Development of ?3-adrenoceptor agonists as antiobesity and antidiabetes drugs in humans: Current status and future prospects

This publication has 85 references indexed in Scilit:

• Meta-analysis of the association of the Trp64Arg polymorphism in the β3 adrenergic receptor with body mass index
  International Journal of Obesity, 1998
• Uncoupling protein‐3: a new member of the mitochondrial carrier family with tissue‐specific expression
  FEBS Letters, 1997
• Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM
  Diabetes, 1997
• The β₃-Adrenergic Receptor — A Cause and Cure of Obesity?
  New England Journal of Medicine, 1995
• Distribution of β3-adrenoceptor mRNA in human tissues
  European Journal of Pharmacology: Molecular Pharmacology, 1995
• The 5′ Flanking Region of the Rat β₃-Adrenergic Receptor Gene: Divergence with the Human Gene and Implications for Species-Specific Gene Expression
  DNA Sequence, 1994
• Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent .beta.-adrenergic agonist virtually specific for .beta.3 receptors. A promising antidiabetic and antiobesity agent
  Journal of Medicinal Chemistry, 1992
• Removal of phosphorylation sites from the β2-adrenergic receptor delays onset of agonist-promoted desensitization
  Nature, 1988
• Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs
  Nature, 1984
• Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats
  The American Journal of Clinical Nutrition, 1983